ArticleWorld journal of surgical oncology2026
Development of a predictive model for pathological complete response following neoadjuvant immunotherapy and chemotherapy in locally advanced resectable esophageal squamous cell carcinoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral Blood Biomarkers for Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNeoadjuvant immunotherapy and chemotherapy (nICT) has demonstrated substantial therapeutic efficacy in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). This study aimed to develop a model to predict the pathological complete response (pCR) following neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC).
methodsIn total, 517 patients with LA-ESCC from two hospitals who underwent nICT or chemotherapy were enrolled between July 2018 and June 2025. The patients were subsequently divided into training, internal validation, and external validation cohorts. All patients received chemotherapy or the same chemotherapy regimen in combination with immunotherapy; both regimens were administered every 3 weeks for 2–4 cycles. Univariate and multivariate logistic regression analyses were used to identify independent predictors of pCR. The predictive performance of the nomograms was further assessed using receiver operating characteristic (ROC) curve analysis, decision curve analysis curves, and clinical impact curves.
resultsAmong the patients included in the study, 29.21% achieved pCR. Multivariate regression analysis revealed that independent risk factors for pCR included differentiation, treatment type, preoperative albumin level, pretreatment neutrophil-to-lymphocyte ratio, and pretreatment lymphocyte-to-monocyte ratio. The numbers 1 after the abbreviations represent pretreatment, and 2 represent preoperative values, respectively. The AUC was 0.809 for the training group, 0.786 for the internal validation group, and 0.806 for the external validation group.
conclusionsThis model demonstrated good predictive performance for pCR following neoadjuvant therapy in patients with ESCC based on a multicenter database, supporting clinical decision-making and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.